SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus receives final approval for Etodolac ER Tablets

30 Jan 2014 Evaluate

Zydus Cadila has received the final approval from the United States Food and Drugs Administration (USFDA) to market Etodolac Extended-release Tablets USP, 400 mg, 500 mg, and 600 mg. The drug is prescribed for treatment of juvenile arthritis, rheumatoid arthritis and osteoarthritis. The group now has 88 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.

Cadila Healthcare, the flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×